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The clinical beneﬁts of repetitive transcranial magnetic stimulation (rTMS) for Parkinson’s disease (PD) remain controversial. We
performed a comprehensive study to examine whether rTMS is a safe and eﬀective treatment for PD. Twelve PD patients received
rTMS once a week. The crossover study design consisted of 4-week sham rTMS followed by 4-week real rTMS. The Uniﬁed
Parkinson’s Disease Rating Scale (UPDRS), Modiﬁed Hoehn and Yahr Stage, Schwab and England ADL Scale, Actigraph, Mini-
Mental State Examination, Hamilton Depression Scale, Wechsler Adult Intelligence Scale-revised, and cerebral blood ﬂow (CBF)
and cerebrospinal ﬂuid (CSF) examinations were used to evaluate the rTMS eﬀects. Under both drug-on and drug-oﬀ conditions,
the real rTMS improved the UPDRS scores signiﬁcantly, while the sham rTMS did not. There were no signiﬁcant changes in the
results of the neuropsychological tests, CBF and CSF. rTMS seems to be a safe and eﬀective therapeutic option for PD patients,
especially in a wearing-oﬀ state.
1.Introduction
Parkinson’s disease (PD) is the second most common neu-
rodegenerative disease after Alzheimer’s disease. The preva-
lence of PD in Japan has been estimated to be about 100 per
100,000 population [1]. The exact etiology and pathogenesis
of PD remain unknown at present [2–5]. The treatments
for PD consist of antiparkinsonian drugs, such as L-dopa,
and stereotactic brain surgery. Although these treatments
are eﬀective for PD symptoms, there are several therapeutic
problems, such as the on-and-oﬀ phenomenon. Therefore,
to overcome the problems, some therapeutic trials for PD
are being conducted. Among them, repetitive transcranial
magnetic stimulation (rTMS) has been used with some PD
patients. In 1994, Pascual-Leone et al. reported that rTMS
improved the ﬁne movement of the upper extremities in
patients with PD [6]. Since then, clinical trials of rTMS for
PD have been reported, many of which indicated the eﬃcacy
of rTMS on the symptoms of PD [7–11]; however, others did
not [12–14]. Moreover, no study has performed a compre-
hensive analysis including examinations of neuropsycholog-
ical status, cerebral blood ﬂow (CBF), and cerebrospinal
ﬂuid (CSF). Here, we report a comprehensive clinical trial of
rTMS for PD with blind tests of motor functions.
2. Patients andMethods
2.1. Patients. Twelve PD patients (seven men and ﬁve wom-
en) with a mean age of 69.2 years (range: 57–78 years) were
includedinthisstudy(Table 1).Weusedthediagnosticcrite-
riarecommendedbythe“MulticentricResearchStudyonthe
Skill and Indication of Surgical Therapy for PD,” a research
group supported by the Japanese government. In brief, PD
was deﬁned as the presence of all of the following ﬁve items:
(1) insidious onset after 20 years of age, (2) resting tremor
of 4–6Hz or cogwheel rigidity with akinesia or small-step
gait, (3) apparent improvement of parkinsonism by L-dopa,
a dopamine receptor agonist, or an anticholinergic agent,
(4) no history of administration of drugs known to cause
parkinsonism, and (5) exclusion of symptomatic parkin-
sonism, such as vascular parkinsonism, multiple system
atrophy, progressive supranuclear palsy, or normal-pressure2 ISRN Neurology
hydrocephalus.Allthepatientsgaveinformedconsentbefore
entering the study. The Ethical Committee of Yamagata
University, Faculty of Medicine, approved the study.
2.2. Protocol of rTMS Treatment. TMS was performed with
an SNM-1100 magnetic stimulator with a YM-121B large
round coil (Nihon Koden, Tokyo, Japan). The stimulus
parameters and the treatment protocol in the present study
were according to the study of Shimamoto and Shigemori
[7], which showed a therapeutic eﬀect of TMS on the
symptoms of PD. In brief, the stimulus intensity was set at
700V, and the stimulus frequency was 0.2Hz. To stimulate
the motor and supplemental motor areas, the real TMS was
applied in the frontal region with the coil placed horizontally
at 3cm anterior from the vertex to the lateral angle of the
eyes.TherealTMSinducedamotor-evokedpotential(MEP)
of the muscles of the lower extremities by stimulating the
motorareaofthecerebralcortex.TheshamTMSwasapplied
with the coil placed vertically at 5% anterior from Fz accord-
ing to the 10–20 system. The sham TMS did not induce
any MEP. The real and sham stimulations were applied
30 times in the clockwise direction and 30 times in the
counterclockwise direction by the electric current in the coil.
The rTMS study design consisted of sham rTMS treatments
for the ﬁrst four weeks followed by real rTMS treatments for
thenextfourweeks.BoththeshamandrealrTMStreatments
were performed once per week. The study design was in
accordance with the recommendation for rTMS proposed by
the Japanese Society of Clinical Neurophysiology [15].
2.3. Estimation of Therapeutic Outcome. For the quantitative
estimationoftheoutcomeofrTMStreatments,thefollowing
clinical test batteries were used. The motor function and
severity of PD were estimated by the Uniﬁed Parkinson’s
Disease Rating Scale (UPDRS), Modiﬁed Hoehn and Yahr
Stage, Schwab and England ADL Scale, and Actigraph. For
the estimation of the psychiatric eﬀects of rTMS, the Mini-
Mental State Examination (MMSE), Hamilton Depression
Scale (HAM-D), and Wechsler Adult Intelligence Scale-
revised (WAIS-R) were used. For the estimation of changes
in cerebral blood ﬂow (CBF) and possible harmful eﬀects
on the brain, single photon emission computed tomography
(SPECT) and cerebrospinal ﬂuid (CSF) examinations were
conducted, respectively.
2.4. Motor Function and Severity of PD. Board-certiﬁed neu-
rologists blindly estimated the motor function and severity
of the parkinsonian symptoms. Without having any infor-
mation of the patients on the drug-on or drug-oﬀ and the
conditions of real or sham rTMS, the neurologists viewed
a video record of each patient under six conditions: before
shamrTMS(drug-onanddrug-oﬀ),aftershamrTMS(drug-
on and drug-oﬀ), and after real rTMS (drug-on and drug-
oﬀ). Under the drug-on condition, patients took antiparkin-
sonian drugs as prescribed. Under the drug-oﬀ condition,
the morning doses of L-dopa compounds, bromocriptine,
amantadine, and trihexiphenidyl were aborted on the exam-
ination day. The doses of pergolide were stopped from the
night of the day before the examination day. The doses of
cabergoline and selegiline were stopped from the morning
of the day before the examination day. Patients took the
prescribed antiparkinsonian drugs immediately after the
drug-oﬀ examinations.
UPDRS was scored at six states: before treatment (drug-
on and drug-oﬀ), after sham rTMS treatment (drug-on
and drug-oﬀ), and after real rTMS treatment (drug-on and
drug-oﬀ). The Modiﬁed Hoehn and Yahr Stage was used to
estimate the severity of PD patients. Stage 0 indicates no
symptoms, and Stage 5, the worst state. The Schwab and
England ADL Scale is a scale of activity of daily life, and it
is scored from 0 to 100% according to the independence of
voluntary actions in daily life. The Modiﬁed Hoehn and Yahr
Stage and Schwab and England ADL Scale were scored under
the same six conditions as for UPDRS scoring.
An Actigraph is a wrist watch-like electronic device
that records the frequency of arm movements (Ambulatory
Monitoring, Inc., Ardsley, NY, USA) [16, 17]. The device
was set to the Zero Crossing Mode, which counts the times
of acceleration over 0.1G. The Actigraph examination was
performed under three states: before treatment, after sham
rTMS treatment, and after real rTMS treatment. Patients
wore the device on the nondominant arm for three days in
each state. We analyzed the acceleration count data collected
by the Actigraph with “Action W” software (supplied with
the device) and obtained the mean counts per minute and
the percentage of time of resting (the period that no count
was recorded in a minute) while the subjects were awake and
asleep.
2.5. Psychiatric Eﬀects. The eﬀects on the patients’ psychi-
atric conditions were examined by the MMSE, WAIS-R,
and HAM-D. The MMSE is a question battery consisting
of orientation, registration of words, attention, calculation,
recalling of words, language, and visual construction [18].
Intelligence was also measured by the WAIS-R. Depressive
symptoms were estimated using the HAM-D [19]. The
MMSE, WAIS-R, and HAM-D were scored under the three
conditions: before treatment, after sham rTMS treatment,
and after real rTMS treatment.
2.6. Measurements of CBF. CBF was estimated by brain
SPECT. 133Xe was used as a radionuclide. CBF was measured
under three conditions: before treatment, after sham rTMS
treatment, and after real rTMS treatment.
2.7. Examination of CSF. CSF examinations were performed
twice: before sham rTMS treatment and after real rTMS
treatment. Total protein, monoamine metabolites (homov-
anillic acid (HVA), 5-hydroxy indoleacetic acid (5-HIAA),
3-methoxy-4-hydroxyphenylethylene glycol (MHPG)), and
neuron-speciﬁc enolase (NSE) in CSF were measured. The
total protein concentration was determined by the pyro-
gallol-red method. The concentrations of HVA, 5-HIAA,
and MHPG were determined by high-performance liquid
chromatography(HPLC)[20].NSEwasdeterminedwiththe
radioimmunoassay [21].ISRN Neurology 3
2.8. Statistical Analysis. Statistical analysis was performed
with the SPSS 11.0 statistical analysis package (SPSS Inc.,
Chicago, Ill, USA). The repeated measures ANOVA (analysis
of variance) were used to analyze the results of the UPDRS,
Modiﬁed Hoehn and Yahr Stage, Schwab and England ADL
Scale, Actigraph, MMSE, HAM-D, and CBF examinations.
The paired t-test with Bonferroni correction was used for
post hoc analysis of the results of UPDRS. The one-way
ANOVA was used to analyze the results of WAIS-R. The
paired t-test was used to analyze the results of CSF exami-
nations. Statistical signiﬁcance was accepted at P<0.05.
3. Results
Subjective improvements of resting tremor (ﬁve patients),
painful dystonia of the legs (one patient), voice loudness
(three patients), bending posture (one patient), wearing-oﬀ
phenomenon (one patient), and akinesia (one patient) were
observed after the rTMS treatments, and these lasted for one
to three months.
Under the drug-on conditions, the UPDRS scores before
treatment, after sham rTMS, and after real rTMS were
48.45 ± 12.36 (mean±standard deviation), 43.58 ± 12.33,
and 40.15 ± 11.99, respectively (Table 2). Through the three
examinations, the UPDRS scores changed signiﬁcantly (P =
0.006,repeatedmeasuresANOVA).TherealrTMStreatment
improved the UPDRS scores signiﬁcantly (P = 0.029, paired
t-test with Bonferroni correction), while the sham rTMS
treatment did not (P = 0.066, paired t- t e s tw i t hB o n f e r r o n i
correction) (Table 2). The Modiﬁed Hoehn and Yahr Stages
before treatment, after sham rTMS, and after real rTMS were
2.92±0.56, 2.75±0.69, and 2.88±0.57, respectively, and did
not show signiﬁcant changes (P = 0.132, repeated measures
ANOVA) (Table 2). Schwab and England ADL scales before
treatment, after sham rTMS, and after real rTMS were
73.33 ±14.35, 72.50 ±15.45, and 75.00 ±14.46, respectively,
and did not show signiﬁcant changes (P = 0.442, repeated
measures ANOVA) (Table 2).
Under the drug-oﬀ conditions, the UPDRS scores before
treatment, after sham rTMS, and after real rTMS were
53.55 ± 19.96, 48.78 ± 14.32, and 44.29 ± 15.40, respectively
(Table 2). Through the three examinations, the UPDRS
scores under the drug-oﬀ conditions changed signiﬁcantly
(P = 0.003, repeated measures ANOVA). The real rTMS
treatment improved the UPDRS scores signiﬁcantly (P =
0.015, paired t-test with Bonferroni correction), while the
sham rTMS treatment did not (P = 0.454, paired t-test with
Bonferroni correction) (Table 2). The Modiﬁed Hoehn and
Yahr Stages before treatment, after sham rTMS, and after
real rTMS were 2.92 ± 0.56, 2.92 ± 0.70, and 2.88 ± 0.57,
respectively, and did not show signiﬁcant changes (P =
0.590, repeated measures ANOVA) (Table 2). The Schwab
and England ADL scales before treatment, after sham rTMS,
and after real rTMS were 70.00 ± 17.06, 67.50 ± 18.65, and
73.33 ± 13.71, respectively, and did not show signiﬁcant
changes (P = 0.093, repeated measures ANOVA) (Table 2).
The results of the Actigraph examination (mean count
per one minute and percentage of time of resting) while the
subjects were awake or asleep did not change signiﬁcantly
among the three conditions (before treatment, after sham
rTMS, and after real rTMS) (Table 3). The MMSE scores
before treatment, after sham rTMS, and after real rTMS were
25.33±3.03, 25.42±2.97, and 26.58±2.97, respectively, and
the scores slightly improved through the three trials, but the
changes were not signiﬁcant (P = 0.114, repeated measures
ANOVA) (Table 3). The HAM-D scores before treatment,
after sham rTMS, and after real rTMS were 11.25 ± 6.30,
10.33 ± 4.91, and 9.42 ± 4.32, respectively (Table 3). The
scores slightly improved through the sham and real rTMS
treatments, but the change was not signiﬁcant (P = 0.447,
repeated measures ANOVA) (Table 3). In the WAIS-R test,
the intelligence quotients did not change signiﬁcantly among
the three conditions (Table 3). In the CBF examination, no
signiﬁcant changes were observed in the blood ﬂow among
the three conditions (Table 3). In the CSF examination,
the concentrations of HVA, 5-HIAA, MHPG, or NSE did
not signiﬁcantly change between the two conditions (before
rTMS and after real rTMS) (Table 3).
4. Discussion
In the present study, the real rTMS treatments signiﬁcantly
improved the scores of UPDRS in PD; however, the sham
rTMS treatments did not, indicating that rTMS may be
effective for PD symptoms. In the clinical settings, it is a
noteworthy ﬁnding that the rTMS treatment had a thera-
peutic eﬀect under the drug-oﬀ condition, as it is analogous
to the wearing-oﬀ phenomenon. In the advanced stage of
PD, patients suﬀer from the instability of drug eﬀects, such
as the wearing-oﬀ or on-oﬀ phenomenon [22]. The present
result suggests that the real rTMS treatment may be useful to
prevent intensiﬁcation of symptoms due to the wearing-oﬀ
phenomenon in patients with PD.
The scores of Actigraph, Schwab and England ADL Scale,
and Modiﬁed Hoehn and Yahr Stage were not signiﬁcantly
changed before and after rTMS. Since the degree of improve-
ments of PD symptoms by rTMS was small in the present
study, it seems that only the UPDRS was able to detect this
small diﬀerence of the symptomatic improvement of PD. In
otherwords,forthe functionalevaluation ofPDpatients, the
UPDRS seems to be the most sensitive among the functional
measures used.
The present study has several advantages over previous
studies using rTMS for PD. Each study was diﬀerent in terms
of the coils used and the sites, intensities, frequencies, and
total number of stimulations. Accordingly, the results cannot
be compared equally. However, the present study had clear
methodological advantages over previous studies. Firstly,
we applied both the sham and real rTMS treatments in a
crossover design. Secondly, the evaluations were performed
under both drug-on and drug-oﬀ conditions. Thirdly, we
estimated motor functions by the UPDRS score in a blind
manner. Lastly, we performeda comprehensive study includ-
ing the neuropsychological, CBF, and CSF examinations as
well as the motor function of PD.
In the present study, no adverse eﬀects of the rTMS were
observed. The MMSE scores slightly improved through the
three trials, but the changes were not statistically signiﬁcant.4 ISRN Neurology
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Table 2: Changes of UPDRS, UPDRSm, Modiﬁed Hoehn and Yahr stage, and Schwab and England ADL scale by rTMS (sham and real).
(a)
Before rTMS After sham rTMS After real rTMS P value
Drug-on
UPDRS 48.45 ±12.36 43.58 ±12.33 40.15 ±11.99 0.006∗
mH&Y 2 .92 ±0.56 2.75 ±0.69 2.88 ±0.57 0.132
S&E 73.33 ±14.35 72.50 ±15.45 75.00 ±14.46 0.442
Drug-oﬀ
UPDRS 53.55 ±19.96 48.78 ±14.32 44.29 ±15.40 0.003∗
mH&Y 2 .92 ±0.56 2.92 ±0.70 2.88 ±0.57 0.590
S&E 70.00 ±17.06 67.50 ±18.65 73.33 ±13.71 0.093
Repeated measures ANOVA. ∗P<0.05.
(b)
Before rTMS After sham rTMS After real rTMS Sham (1) Real (2) Overall (3)
Drug-on UPDRS 48.45 ±12.36 43.58 ±12.33 40.15 ±11.99 0.066 0.029∗ 0.005∗
Drug-oﬀ UPDRS 53.55 ±19.96 48.78 ±14.32 44.29 ±15.40 0.454 0.015∗ 0.026∗
Paired t-test with Bonferroni correction. ∗P<0.05. Drug-on: taking drugs as prescribed, drug-oﬀ: according to Table 2. UPDRS: uniﬁed Parkinson’s Disease
Rating Scale. S&E: Schwab and England ADL scale, mH & Y: modiﬁed Hoehn and Yahr stage. (1): P value for between before rTMS and after sham rTMS.
(2): P value for between after sham rTMS and after real rTMS. (3): P value for between before rTMS and after real rTMS.
Table 3: Changes of Actigraph, MMSE, HAM-D, WAIS-R, cerebral blood ﬂow, and cerebrospinal ﬂuid by rTMS (sham and real).
Before rTMS After sham rTMS After real rTMS P value
Actigraph up state (1) Mean counts per one minute 131.2 ±17.0 131.4 ±27.2 130.1 ±31.7 0.977
Resting (%) 17.1 ±4.51 8 .9 ±7.21 9 .0 ±8.6 0.611
Actigraph down state (2) Mean counts per one minute 31.0 ±24.43 1 .0 ±19.63 5 .2 ±26.8 0.652
Resting (%) 80.8 ±17.57 6 .7 ±15.27 5 .9 ±15.9 0.593
MMSE 25.33 ±3.03 25.42 ±2.97 26.58 ±2.97 0.114
HAM-D 11.25 ±6.30 10.33 ±4.91 9.42 ±4.32 0.447
WAIS-R# Verbal IQ 97.30 ±20.63 101.63 ±18.62 98.80 ±20.80 0.901
Performance IQ 89.60 ±10.45 96.00 ±9.41 99.80 ±9.36 0.159
Total IQ 93.40 ±16.78 99.00 ±14.68 98.00 ±16.93 0.742
Cerebral blood ﬂow (ml/min/100g) 47.50 ±3.26 45.75 ±3.55 47.75 ±3.96 0.078
Cerebrospinal ﬂuid## Total protein (mg/dl) 41.2 ±13.13 9 .9 ±14.7 0.579
HVA (ng/ml) 35.3 ±17.93 6 .2 ±12.8 0.817
5-HIAA (ng/ml) 13.4 ±7.71 3 .7 ±7.6 0.799
MHPG (ng/ml) 9.5 ±2.99 .0 ±2.5 0.368
NSE (ng/ml) 15.5 ±9.21 5 .4 ±7.6 0.952
Repeated measures ANOVA, ∗P<0.05. #One-way ANOVA. ##Paired t-test. (1): Actigraph record while awaken. (2): Actigraph record while sleeping. MMSE:
Mini-Mental State Examination, HAM-D: Hamilton Depression Scale. WAIS-R: Wechsler Adult Intelligence Scale-Revised, IQ: intellectual quotient.H V A :
homovanillic acid; 5-HIAA: 5-hydroxy indoleacetic acid; MHPG: 3-methoxy-4-hydroxyphenylethylene glycol. NSE: neuron-speciﬁc enolase.
In the WAIS-R tests, the verbal IQ and performance IQ
showed a slight improvement but without a statistical sig-
niﬁcance. The possibility cannot be excluded that, although
not signiﬁcant, the slight improvement of the results of the
WAIS-R tests may be due to a learning eﬀect. In any case,
the results seem to indicate that the rTMS treatment may
nothaveanysigniﬁcantbeneﬁcialoradverseeﬀectonmental
and psychiatric conditions. In addition, the rTMS treatment
in our protocol did not appear to cause any damage in the
central nervous system of the patients because the CBF and
CSF concentrations of total protein and NSE did not change
before and after rTMS. NSE is known to increase in CSF
when neurons are injured rapidly, as in Creutzfeldt-Jakob
disease and in the acute stage of cerebral infarction [23, 24].
The mechanism of the therapeutic eﬀect of rTMS for PD
hasnotbeenclariﬁed.Dopaminergicantiparkinsoniandrugs
have been reported to increase the CSF concentration of the
monoamine metabolites, including HVA [25]. In the present
study, the motor symptoms were signiﬁcantly improved in
the PD patients examined, but the CSF concentrations of
HVA, 5-HIAA, and MHPG did not increase. The results
suggestthattheimprovementofPDsymptomsbyrTMSmay
notbemediatedbyanincreaseinthemonoamineconcentra-
tion. Furthermore, the rTMS treatment did not increase CBF6 ISRN Neurology
in the present study, indicating that the therapeutic eﬀects of
therTMSintheprotocolmaynotbemediatedbyanincrease
in CBF.
Onepossibleexplanationforthetherapeuticeﬀectsofthe
rTMSonPDsymptomsisasfollows.InPD,theexcitabilityof
thecerebralcortexissuspectedtobedecreasedbecauseofthe
altered excitatory inputs from the thalamus; TMS may com-
pensate for this decreased excitability of the cerebral cortex
[26–28]. Another explanation is that TMS may improve the
imbalance between the substantia nigra pars reticulata and
the internal segment of the globus pallidus. The feedback
system from the cerebral cortex to the striatum may be
stimulated with rTMS, resulting in the normalization of the
imbalance. Further studies are needed to elucidate the exact
therapeutic mechanism by rTMS.
In conclusion, the present study demonstrates that rTMS
s e e m st ob eas a f ea n de ﬀective therapeutic option for PD
symptoms, especially in the wearing-oﬀ state.
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